Business Wire

AgNovos Healthcare Completes Enrollment for CONFIRM Clinical Study

Share

AgNovos Healthcare, a developer of new therapies that leverage proprietary, bone-building technology and regenerative medicine to address unmet needs in the treatment of bone disease, announced today the completion of enrollment for its CONFIRM study. CONFIRM is designed to generate additional data supporting the safety and efficacy of the Company’s AGN1 Local Osteo-Enhancement Procedure (LOEP) product when used in post-menopausal women with osteoporosis. With 60 subjects, CONFIRM is the fourth and largest study of LOEP to complete enrollment. This study includes women receiving unilateral or bilateral treatment with the CE-marked AGN1 LOEP kit.

“The completion of patient enrollment in CONFIRM is an important development for the Company.” said Adam Lowe, Senior Vice President of Clinical Research and Quality at AgNovos Healthcare. He continued, “we look forward to completing the collection, analysis and publication of this data.”

Dr. Jo De Schepper is an orthopedic surgeon and principal investigator at the highest enrolling site, AZ Nikolaas in Sint Niklaas, Belgium. He commented, “the response to the study and technology has been very positive. I know my colleagues in orthopedics and metabolic bone health are interested to see this data. We know the impact that fragility fractures associated with osteoporotic bone loss have on our local communities and are encouraged by the promise of this therapeutic approach.”

CONFIRM patients are being enrolled in an extension study to evaluate LOEP’s impact during the five years following treatment.

About AGN1 LOEP Hip Kit

The AGN1 LOEP Hip Kit contains the instruments and materials to perform a minimally invasive procedure to implant AGN1, a proprietary, calcium-based, osteoconductive, and tri-phasic implant material. AGN1 is uniquely formulated with a cell-friendly surface architecture and a resorption profile that enables the rapid formation of new bone. Preclinical and clinical research has shown that AGN1 LOEP treatment delivers immediate, substantial and durable increase in the strength of osteoporotic femurs. The kit is available in select markets under the brand name OSSURE® LOEP kit.

About AgNovos Healthcare

AgNovos Healthcare is a developer of new therapies that leverage proprietary, bone-building technology and regenerative medicine to address unmet needs in the treatment of bone disease. AgNovos Healthcare is privately held and has its corporate headquarters in New York City with manufacturing, research & development, and corporate support services located in Rockville, MD. www.agnovos.com

CAUTION this press release refers to a CE-marked device. The OSSURE Local Osteo-enhancement (LOEP) Kit is not cleared in the United States.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

James Pilachowski
Senior Vice President, Hip Program and Marketing
+1 646 502 5868
jpilachowski@agnovos.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Everdome Secures US$10 million Investment Commitment from GEM Digital Limited9.8.2022 11:00:00 CEST | Press release

Everdome, the most hyper-realistic metaverse, has announced that GEM Digital Limited (GEM), a Bahamas-based digital asset investment firm that sources, structures and invests in utility tokens listed on over 30 CEXs and DEXs globally, has agreed to an investment commitment of US$10 million into the UAE-based metaverse company through a structured token subscription agreement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220809005321/en/ Everdome Secures US$10 million Investment Commitment from GEM Digital Limited (Photo: AETOSWire) The announcement comes during a period of heightened activity for Everdome, particularly in terms of its product roll-out and the company’s auction of metaverse land plots. Since June 2022, a total of 11,700 plots (97%) located throughout the Everdome metaverse were sold throughout an eight week auction experience. In total, plots were purchased for upwards of US$18.6 million, which is equivalen

OPEX ® to Exhibit Warehouse Automation Solutions at UK Event for Supply Chain and Logistics Professionals9.8.2022 10:00:00 CEST | Press release

OPEX® Corporation, a global leader in Next Generation Automation for almost 50 years, is introducing leading-edge Warehouse Automation technology to attendees of IMHX, an intralogistics event for professionals involved in the handling, movement or transportation of goods through the supply chain. IMHX 2022 will be held 5-9 September at the NEC Birmingham. This will be OPEX’s first time exhibiting at IMHX and the first time the company’s Sure Sort® robotic sorting system will be on display at a trade show in the UK. “Sure Sort is a scalable and cost-effective alternative to traditional put wall sorting,” said Nicolas Dewit, Director of Business Development for Europe, Middle East, and Asia (EMEA), OPEX Warehouse Automation. “It is an ideal ecommerce solution for micro-fulfillment centers, retail stores, and distribution centers that demand a small footprint, high accuracy, speed, and high productivity in a system that does not increase labor.” Sure Sort robotic delivery vehicles, iBOTs®

Agoda and Alipay+ Expand on Their Partnership to Offer Greater Rewards to Travelers Through Digital Payment Methods9.8.2022 07:39:00 CEST | Press release

Agoda and Alipay+ today announced a new partnership that will leverage Alipay+ solutions on the Agoda platform for better customer benefits and rewards. This is in addition to the existing integration of multiple digital wallets, namely the AlipayHK, GCash and TrueMoney, through Alipay+ on Agoda’s platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220808005877/en/ (Photo: Business Wire) With this new partnership, multiple Alipay+ marketing solutions, including Alipay+ Rewards and its in-cashier marketing services, can be used for discounts distribution and redemption on Agoda. This enables Agoda to enhance its transaction conversion rate, while travelers can enjoy great returns in countries and regions like Hong Kong SAR of China, the Philippines, and Thailand – with the possibility of more regions to come in the future. As the global economy recovers from the COVID-19 pandemic, the online travel industry has seen a v

Abionic Receives IVDR Certification for Its Predictive Ultra-Rapid Sepsis Test Allowing the Management of Antibiotic Administration9.8.2022 06:00:00 CEST | Press release

Abionic SA, a developer of disruptive nanotechnology-based diagnostic solutions, has announced that its Pancreatic Stone Protein (PSP) test on the abioSCOPE® has been certified by BSI certification agency as complying with the European In-vitro Diagnostic Regulation (IVDR), EU 2017/746. This certification granted by notified bodies like BSI is required for in-vitro diagnostics to continue being sold in the European Union. The IVDR’s extensive requirements were adopted by the European Parliament in 2017 and must now be implemented by May 26, 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220808005159/en/ FIVE MINUTES TO SAVE LIVES - Immediate clinical decision-making at your fingertips (Photo: Business Wire) IVDR becomes mandatory as of May 26, 2022. There are also transitional rules that will allow well-established instruments that have not been IVDR certified, but that entered the EU before, to still be sold until 202

A Digital Twin of Kabuki Actor Shido Nakamura Created with NTT’s Another Me Technology Debuts at “Cho Kabuki 2022 Powered by NTT”9.8.2022 05:03:00 CEST | Press release

NTT Corporation (President: Akira Shimada, “NTT”) and Shochiku Co., Ltd. (President & CEO: Junichi Sakamoto) have announced "Cho Kabuki 2022 Powered by NTT" sponsored by Shochiku, with the first act starring Shido Nakamura's digital twin, “Shido Twin.” The debut of Shido Twin showcases NTT’s research and development of a computer that reproduces people as digital twins and is the first step in the social implementation of this new technology. We hope you will come and witness the birth of Shido Nakamura reproduced as a digital twin. Created in collaboration with Shochiku Co., Ltd., the Shido Twin autonomously reproduces the gestures of Shido Nakamura, who plays the leading role in Cho-kabuki, using the body motion generation technology of Another Me. Another Me is a technology born out of NTT’s Digital Twin Computing1 concept. With Another Me, we aim to allow individuals to create an “alternative self” in the digital space, dramatically increasing the opportunities to flourish and grow

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom